Psoriatic arthritis

ABSTRACT Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Dermatologic therapy 2009-01, Vol.22 (1), p.40-55
1. Verfasser: Gladman, Dafna D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 55
container_issue 1
container_start_page 40
container_title Dermatologic therapy
container_volume 22
creator Gladman, Dafna D.
description ABSTRACT Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. New classification criteria should facilitate case definition of PsA. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with potential to controlling the inflammation and arresting the progression of joint damage.
doi_str_mv 10.1111/j.1529-8019.2008.01215.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66940235</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66940235</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4815-fc801c6ee5b0fddb7df5e522c26d66c4f957f8a6c23da15d712ad5712ee57213</originalsourceid><addsrcrecordid>eNqNkMFPwjAUhxujEURP3g0nb5ttt3brwYMBASNRDiQaLy-l7WJxOGxHhP_ezhG82kP7kn7fe3k_hPoExyScm2VMGBVRjomIKcZ5jAklLN4eoe7h4zjUieARpoJ30Jn3SxwokZBT1CGCUsoI76LLma-clbVVfenqd2dr68_RSSFLby72bw_NR_fzwSSaPo8fBnfTSKU5YVGhwhjFjWELXGi9yHTBDKNUUa45V2khWFbkkiuaaEmYzgiVmoU7GBklSQ9dt23XrvraGF_DynplylJ-mmrjgXORYpqwAOYtqFzlvTMFrJ1dSbcDgqHJA5bQrA3N2tDkAb95wDaoV_sZm8XK6D9xH0AAblvg25Zm9-_GMJxPmir4UetbX5vtwZfuA3iWZAxensaAZ-l49Pb4Cjz5AdrsfAY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66940235</pqid></control><display><type>article</type><title>Psoriatic arthritis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Gladman, Dafna D.</creator><creatorcontrib>Gladman, Dafna D.</creatorcontrib><description>ABSTRACT Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. New classification criteria should facilitate case definition of PsA. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with potential to controlling the inflammation and arresting the progression of joint damage.</description><identifier>ISSN: 1396-0296</identifier><identifier>EISSN: 1529-8019</identifier><identifier>DOI: 10.1111/j.1529-8019.2008.01215.x</identifier><identifier>PMID: 19222516</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Arthritis, Psoriatic - classification ; Arthritis, Psoriatic - drug therapy ; Arthritis, Psoriatic - mortality ; Arthritis, Psoriatic - physiopathology ; Biological Products - immunology ; Biological Products - therapeutic use ; Clinical Trials as Topic ; Disease Progression ; epidemiology ; Humans ; Joints - physiopathology ; Prognosis ; psoriatic arthritis ; Quality of Life ; Remission Induction - methods ; treatment</subject><ispartof>Dermatologic therapy, 2009-01, Vol.22 (1), p.40-55</ispartof><rights>2009 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4815-fc801c6ee5b0fddb7df5e522c26d66c4f957f8a6c23da15d712ad5712ee57213</citedby><cites>FETCH-LOGICAL-c4815-fc801c6ee5b0fddb7df5e522c26d66c4f957f8a6c23da15d712ad5712ee57213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1529-8019.2008.01215.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1529-8019.2008.01215.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19222516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gladman, Dafna D.</creatorcontrib><title>Psoriatic arthritis</title><title>Dermatologic therapy</title><addtitle>Dermatol Ther</addtitle><description>ABSTRACT Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. New classification criteria should facilitate case definition of PsA. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with potential to controlling the inflammation and arresting the progression of joint damage.</description><subject>Arthritis, Psoriatic - classification</subject><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Arthritis, Psoriatic - mortality</subject><subject>Arthritis, Psoriatic - physiopathology</subject><subject>Biological Products - immunology</subject><subject>Biological Products - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Disease Progression</subject><subject>epidemiology</subject><subject>Humans</subject><subject>Joints - physiopathology</subject><subject>Prognosis</subject><subject>psoriatic arthritis</subject><subject>Quality of Life</subject><subject>Remission Induction - methods</subject><subject>treatment</subject><issn>1396-0296</issn><issn>1529-8019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMFPwjAUhxujEURP3g0nb5ttt3brwYMBASNRDiQaLy-l7WJxOGxHhP_ezhG82kP7kn7fe3k_hPoExyScm2VMGBVRjomIKcZ5jAklLN4eoe7h4zjUieARpoJ30Jn3SxwokZBT1CGCUsoI76LLma-clbVVfenqd2dr68_RSSFLby72bw_NR_fzwSSaPo8fBnfTSKU5YVGhwhjFjWELXGi9yHTBDKNUUa45V2khWFbkkiuaaEmYzgiVmoU7GBklSQ9dt23XrvraGF_DynplylJ-mmrjgXORYpqwAOYtqFzlvTMFrJ1dSbcDgqHJA5bQrA3N2tDkAb95wDaoV_sZm8XK6D9xH0AAblvg25Zm9-_GMJxPmir4UetbX5vtwZfuA3iWZAxensaAZ-l49Pb4Cjz5AdrsfAY</recordid><startdate>200901</startdate><enddate>200901</enddate><creator>Gladman, Dafna D.</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200901</creationdate><title>Psoriatic arthritis</title><author>Gladman, Dafna D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4815-fc801c6ee5b0fddb7df5e522c26d66c4f957f8a6c23da15d712ad5712ee57213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Arthritis, Psoriatic - classification</topic><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Arthritis, Psoriatic - mortality</topic><topic>Arthritis, Psoriatic - physiopathology</topic><topic>Biological Products - immunology</topic><topic>Biological Products - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Disease Progression</topic><topic>epidemiology</topic><topic>Humans</topic><topic>Joints - physiopathology</topic><topic>Prognosis</topic><topic>psoriatic arthritis</topic><topic>Quality of Life</topic><topic>Remission Induction - methods</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gladman, Dafna D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatologic therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gladman, Dafna D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psoriatic arthritis</atitle><jtitle>Dermatologic therapy</jtitle><addtitle>Dermatol Ther</addtitle><date>2009-01</date><risdate>2009</risdate><volume>22</volume><issue>1</issue><spage>40</spage><epage>55</epage><pages>40-55</pages><issn>1396-0296</issn><eissn>1529-8019</eissn><abstract>ABSTRACT Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. New classification criteria should facilitate case definition of PsA. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with potential to controlling the inflammation and arresting the progression of joint damage.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>19222516</pmid><doi>10.1111/j.1529-8019.2008.01215.x</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1396-0296
ispartof Dermatologic therapy, 2009-01, Vol.22 (1), p.40-55
issn 1396-0296
1529-8019
language eng
recordid cdi_proquest_miscellaneous_66940235
source MEDLINE; Access via Wiley Online Library
subjects Arthritis, Psoriatic - classification
Arthritis, Psoriatic - drug therapy
Arthritis, Psoriatic - mortality
Arthritis, Psoriatic - physiopathology
Biological Products - immunology
Biological Products - therapeutic use
Clinical Trials as Topic
Disease Progression
epidemiology
Humans
Joints - physiopathology
Prognosis
psoriatic arthritis
Quality of Life
Remission Induction - methods
treatment
title Psoriatic arthritis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-31T10%3A44%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psoriatic%20arthritis&rft.jtitle=Dermatologic%20therapy&rft.au=Gladman,%20Dafna%20D.&rft.date=2009-01&rft.volume=22&rft.issue=1&rft.spage=40&rft.epage=55&rft.pages=40-55&rft.issn=1396-0296&rft.eissn=1529-8019&rft_id=info:doi/10.1111/j.1529-8019.2008.01215.x&rft_dat=%3Cproquest_cross%3E66940235%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66940235&rft_id=info:pmid/19222516&rfr_iscdi=true